AcquisitionOther
N2OFF, Inc. acquired Next-Gen Computational Drug Discovery Company, Targeting Hard To Treat Cancers Neve Yarak, Israel, February 26, 2025
Public deal record from 8-K. The source names the buyer and target, and terms are shown only when the filing or announcement discloses them.
Deal tape row
N2OFF, Inc. -> Next-Gen Computational Drug Discovery Company, Targeting Hard To Treat Cancers Neve Yarak, Israel, February 26, 2025 · $1.6 million
Furthermore, by leveraging its advanced in-vitro screening systems related to mitochondria, MitoCareX corroborates the anti-cancer biological activity of small molecules discovered through its computational platform.
Open source record (SEC) ↗